Page last updated: 2024-10-27

fluconazole and Pulmonary Alveolar Proteinosis

fluconazole has been researched along with Pulmonary Alveolar Proteinosis in 1 studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

Pulmonary Alveolar Proteinosis: A PULMONARY ALVEOLI-filling disease, characterized by dense phospholipoproteinaceous deposits in the alveoli, cough, and DYSPNEA. This disease is often related to, congenital or acquired, impaired processing of PULMONARY SURFACTANTS by alveolar macrophages, a process dependent on GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, YC1
Chew, GT1
Robinson, BW1

Other Studies

1 other study available for fluconazole and Pulmonary Alveolar Proteinosis

ArticleYear
Pulmonary and meningeal cryptococcosis in pulmonary alveolar proteinosis.
    Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:6

    Topics: Adult; Antifungal Agents; Cryptococcosis; Fluconazole; Humans; Lung Diseases, Fungal; Male; Meningit

1999